<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01968499</url>
  </required_header>
  <id_info>
    <org_study_id>002</org_study_id>
    <secondary_id>NNSFC/81170181</secondary_id>
    <nct_id>NCT01968499</nct_id>
  </id_info>
  <brief_title>Pharmacogenetic and Pharmacokinetic Study of Clopidogrel</brief_title>
  <acronym>PPSC</acronym>
  <official_title>Associations of the Pharmacogenetic and Pharmacokinetic Factors With Clopidogrel Low Response and Clinical Outcome in Patients With Coronary Stent Implantation: a Registration Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Natural Science Foundation of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This registration study aims to investigate the associations of the pharmacogenetic and&#xD;
      pharmacokinetic factors with clopidogrel low response and clinical outcome in patients with&#xD;
      coronary artery disease, and provide new pharmacogenetic and pharmacokinetic targets for the&#xD;
      individualized anti-platelet treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Associations of the Pharmacogenetic and Pharmacokinetic Factors With Clopidogrel Low Response&#xD;
      and Clinical Outcome in Patients With Coronary Stent Implantation: a Registration Study&#xD;
&#xD;
      Published data linking clopidogrel non-responsiveness to adverse ischaemic events lead to the&#xD;
      suggestion that the magnitude of platelet inhibition by clopidogrel can be monitored and&#xD;
      individually adjusted. This has been tested in randomised clinical trials (ARCTIC, GRAVITAS&#xD;
      and TRIGGER-PCI), but despite reducing platelet reactivity, a strategy of therapy adjustment&#xD;
      based on platelet function monitoring did not reduce the incidence of cardiac ischaemic&#xD;
      events1, which indicates that most pharmacodynamical tests monitored anti-platelet treatment&#xD;
      failed so far.&#xD;
&#xD;
      We accordingly performed this registration study to investigate whether the pharmacogenetic&#xD;
      and pharmacokinetic factors are associated with clopidogrel low response as well as clinical&#xD;
      outcome, and aimed to provide new targets for the individualized anti-platelet treatment.&#xD;
&#xD;
      Inclusion criteria:&#xD;
&#xD;
        1. Successively recruit all patients who receive stent implantation and take aspirin 100 mg&#xD;
           and clopidogrel 75 mg once daily (7:00 a.m.) for more than 5 days.&#xD;
&#xD;
        2. Patient aged &gt;18 years;&#xD;
&#xD;
        3. Signed inform consent.&#xD;
&#xD;
      Exclusion criteria:&#xD;
&#xD;
        1. intolerant with aspirin or clopidogrel treatment (e.g. allergic reactions or&#xD;
           gastrointestinal bleeding);&#xD;
&#xD;
        2. taking medication that could interfere with the antiplatelet efficacy of clopidogrel&#xD;
           (e.g. vitamin K antagonists, direct oral anticoagulants or nonsteroidal&#xD;
           anti-inflammatory drugs);&#xD;
&#xD;
        3. with myelodysplastic syndrome or abnormal baseline platelet counts of &lt; 80 × 10∧9/L or &gt;&#xD;
           450 × 10∧9/L;&#xD;
&#xD;
        4. hemoglobin &lt; 90g/L;&#xD;
&#xD;
        5. with a history of cerebral hemorrhage within 1 year;&#xD;
&#xD;
        6. in pregnancy.&#xD;
&#xD;
      Clinical data collection:&#xD;
&#xD;
        1. Patients basic characteristics.&#xD;
&#xD;
        2. Diagnosis and complicated diseases.&#xD;
&#xD;
        3. Medical treatment and interventional treatment.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      Blood samples are collected 5 days after the patients' taking clopidogrel to perform the&#xD;
      genetic testing and determine the light transmittancy aggregation (LTA) and the serum levels&#xD;
      of the parent clopidogrel, intermediate and active metabolites of clopidogrel. LTA is to&#xD;
      re-determined 1 month after clopidogrel consumption. Clopidogrel low response is defined as&#xD;
      the inhibition of platelet aggregation (IPA) in response to 5μM ADP is more than 40%.&#xD;
      Clinical follow-up will be performed 1month, 6month, and 1year after the patients' included.&#xD;
      Major adverse cardiovascular events (MACE) is set as death, non-fatal myocardial infarction&#xD;
      (MI), ischemic stroke. Associations of the pharmacogenetic and pharmacokinetic factors with&#xD;
      clopidogrel low response and clinical outcome will be analyzed.&#xD;
&#xD;
      Tests:&#xD;
&#xD;
        1. ADP-induced platelet aggregation: LTA in response to 5μM ADP.&#xD;
&#xD;
        2. Arachidonic acid (AA)-induced platelet aggregation: LTA in response to 1mM AA.&#xD;
&#xD;
        3. Simultaneous detection of clopidogrel, 2-oxo-clopidogrel and its thiol metabolite in&#xD;
           human plasma by the high performance liquid chromatography-tandem mass spectrometry&#xD;
           (HPLC-MS/MS) method.&#xD;
&#xD;
        4. GWAS scan or genotyping of ABCB1,CYP2C19, paraoxonase 1 (PON1), CYP3A5, P2RY12.&#xD;
&#xD;
      Sample size: We plan to recruit 1800 patients.&#xD;
&#xD;
      Clinical follow-up: 1 month, 6 month, and 1 year after the patients' included.&#xD;
&#xD;
      Major adverse cardiovascular events (MACE): Death, non-fatal MI, ischemic stroke.&#xD;
&#xD;
      Minor adverse cardiovascular events: Hospitalization, revascularization, stent thrombosis&#xD;
      (ARC definition) and minor, moderate, and major bleeding (TIMI definition).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">October 17, 2017</completion_date>
  <primary_completion_date type="Actual">October 17, 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Risk ratio</measure>
    <time_frame>1 year after patients' being recruited</time_frame>
    <description>Risk ratio of the genotypes on MACE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk ratio</measure>
    <time_frame>1 year after patients' being recruited</time_frame>
    <description>Risk ratio of the pharmacokinetic results on MACE.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Risk ratio</measure>
    <time_frame>1 month after patients' being recruited</time_frame>
    <description>Risk ratio of the genotypes on clopidogrel low response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk ratio</measure>
    <time_frame>1 month after patients' being recruited</time_frame>
    <description>Risk ratio of the pharmacokinetic results on clopidogrel low response.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Risk ratio</measure>
    <time_frame>1 year after patients' being recruited</time_frame>
    <description>Risk ratios of the genotypes and pharmacokinetic results on the minor adverse cardiovascular events.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1805</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>All recruited patients</arm_group_label>
    <description>Patients who receive stent implantation and aged &gt;18 years.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA samples of all recuited patients are collected and stored for future analysis.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients who receive stent implantation and aged &gt;18 years.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Successively recruit all patients who receive stent implantation and take aspirin 100&#xD;
             mg and clopidogrel 75 mg daily for more than 5 days.&#xD;
&#xD;
          2. Patient aged &gt;18 years;&#xD;
&#xD;
          3. Signed inform consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. intolerant with aspirin or clopidogrel treatment (e.g. allergic reactions or&#xD;
             gastrointestinal bleeding);&#xD;
&#xD;
          2. taking medication that could interfere with the antiplatelet efficacy of clopidogrel&#xD;
             (e.g. vitamin K antagonists, direct oral anticoagulants or nonsteroidal&#xD;
             anti-inflammatory drugs);&#xD;
&#xD;
          3. with myelodysplastic syndrome or abnormal baseline platelet counts of &lt; 80 × 10∧9/L or&#xD;
             &gt; 450 × 10∧9/L;&#xD;
&#xD;
          4. hemoglobin &lt; 90g/L;&#xD;
&#xD;
          5. with a history of cerebral hemorrhage within 1 year;&#xD;
&#xD;
          6. in pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chunjian Li, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>First Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Siller-Matula JM, Jilma B. Why have studies of tailored anti-platelet therapy failed so far? Thromb Haemost. 2013 Oct;110(4):628-31. doi: 10.1160/TH13-03-0250. Epub 2013 Jul 25.</citation>
    <PMID>23884166</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>October 17, 2013</study_first_submitted>
  <study_first_submitted_qc>October 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2013</study_first_posted>
  <last_update_submitted>October 16, 2017</last_update_submitted>
  <last_update_submitted_qc>October 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital with Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Chunjian Li</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>coronary stent implantation; clopidogrel low response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

